East Hanover, New Jersey 07936

  • Overactive Bladder Syndrome

Purpose:

This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.


Criteria:

Inclusion Criteria: - Three symptoms of OAB (urge incontinence, frequency and urgency) for at least six months prior to Visit 2. - Patients capable of independent toileting and able of independently completing the patient diary. Exclusion Criteria: - Patients in whom the use of anticholinergic drugs was contraindicated - Evidence of severe liver disease - Patients with other clinically significant urinary or gynecological conditions Other protocol-defined inclusion/exclusion criteria may apply.


NCT ID:

NCT00171145


Primary Contact:

Study Chair
Novartis
East Hanover NJ


Backup Contact:

N/A


Location Contact:

East Hanover, New Jersey 07936
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.